Indian drugmaker Cipla beats first-quarter profit view on higher domestic demand
The company's consolidated net profit rose 10% to 12.98 billion rupees ($150 million) in the April-June quarter, beating analysts' average estimate of 12.11 billion rupees, per data compiled by LSEG.
Total revenue increased 4% to 69.57 billion rupees, slightly below expectations of 70.64 billion rupees.
Cipla's shares jumped 3.4% after the results and were set for their best day in nearly three months. The stock was the top gainer on the blue-chip Nifty 50 index (.NSEI), opens new tab.
Revenue from India, Cipla's biggest market by sales, climbed 6% to 30.70 billion rupees, while North America revenue fell 7% to 19.33 billion rupees.
The two regions account for three-fourths of the company's total sales.
Cipla said growth in India was led by demand for drugs in therapy areas such as respiratory, urology and anti-infectives.
However, delayed approvals for new drug applications and pricing pressure have weighed on the drugmaker's growth in the U.S.
Drug prices in the U.S. are expected to drop as shortages ease and competition from new drugmakers intensifies, Macquarie analysts said in a pre-earnings note.
Earlier this week, rival Dr Reddy's (REDY.NS), opens new tab missed quarterly profit estimates and flagged increased price erosion in certain key products, including lenalidomide in North America.
($1 = 86.5750 Indian rupees)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
15 minutes ago
- Reuters
India's IndusInd Bank posts quarterly profit drop
BENGALURU, July 28 (Reuters) - India's IndusInd Bank ( opens new tab reported a drop in first quarter profit on Monday, hurt by decline in loans and rise in provisions for potential bad loans. The country's fifth largest private lender by assets said its profit fell 68% to 6.84 billion rupees ($78.93 million) for the quarter ended June 30. In the previous quarter, IndusInd had reported its biggest-ever quarterly loss, as it took a $230 million hit to its accounts in the year ended March 31 due to years of misaccounting of internal derivative trades. ($1 = 86.6600 Indian rupees)
Reuters
an hour ago
- Reuters
Russia-backed Indian refiner Nayara takes Microsoft to court over outage
NEW DELHI, July 28 (Reuters) - Russia-backed Indian refiner Nayara Energy Monday said it has started legal proceedings against Microsoft (MSFT.O), opens new tab following the abrupt and unilateral suspension of critical services by the U.S.-headquarterd software giant. "Microsoft is currently restricting Nayara Energy's access to its own data, proprietary tools, and products—despite these being acquired under fully paid-up licenses," the refiner said in a statement.
Reuters
2 hours ago
- Reuters
Indian drugmaker Torrent Pharma's quarterly profit jumps on strong demand
July 28 (Reuters) - India's Torrent Pharma ( opens new tab reported a 20% jump in its first-quarter profit on Monday, driven by demand for drugs used to treat long-term conditions. The firm's consolidated net profit rose to 5.48 billion rupees ($63.2 million) for the quarter ended June 30, from 4.57 billion rupees year ago. Its total revenue grew 11% to 31.78 billion rupees, surpassing analysts' estimates of 31.57 billion rupees, as per data compiled by LSEG. For further earnings highlights, click. Torrent Pharma, which makes drugs for treating conditions such as diabetes, infections, and cancer, continued to benefit from strong domestic demand for these medicines. Revenue from India, which contributed around 56% to the total, jumped 11% from a year earlier. This was led by strong demand for Torrent's therapies such as cardiovascular, gastro-intestinal and anti-infectives. Diabetes, which is one of Torrent's key therapy areas, led demand in the Indian pharmaceutical market, which grew 8% in June, according to data from India Ratings and Research. PEER COMPARISON * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT APRIL TO JUNE STOCK PERFORMANCE -- $1 = 86.6530 Indian rupees
